C3N Project Webcast with Ginger.io - August 21, 2012
-
Upload
amy-martin -
Category
Health & Medicine
-
view
87 -
download
2
Transcript of C3N Project Webcast with Ginger.io - August 21, 2012
LIVE WEBCAST | FeaturingAugust 21, 2012
C3N Supported by NIH NIDDK R01DK085719
AHRQ R01HS020024 AHRQ U18HS016957
Welcome!• We will pause for questions after
the C3N Project overview, and at
the conclusion of our feature
presentation we will host more
time for Q&A; but you can also
direct questions and comments
anytime using the chat function
• After the presentation, a short
survey will appear – thanks for your
feedback + participation!
• First, a few technology pointers…
Peter Margolis, MD, PhD
Michael Seid, PhD
Mute/ Un-Mute Your Line
Raising Your Hand
4
Raise your hand Lower your hand
Writing Comments & Asking Questions
CLICK HERE TO OPEN BOX.
TYPE YOUR QUESTION HERE!
6
take the conversation to twitter
#C3N@C3NProject@Ginger_io
An Introduction of the C3N Projectwith Dr. Peter Margolis
What if….?
• …we could create a vastly better chronic care system
by harnessing inherent motivation and collective
intelligence of patients and clinicians?
• … this system allowed patients and physicians to
share information, collaborate to solve problems, use
their collective creativity and expertise to act in ways
that improve health?
What is the C3N?
• Self-reinforcing network
• “Lab” and “proving ground”
• A social, technical and scientific platform to support a learning health system
Learning Health Systems
• Patients and providers work together to choose care
based on best evidence
• Drive discovery as natural outgrowth of patient care
• Ensure innovation, quality, safety and value
• All in real-time
Institute of Medicine
Design
Observation
Synthesis
Screen
Test Adapt, Implement & Spread
Prototype testing
Pilottesting
Concept design
Generate new ideas Test new ideas Spread new ideas
C3N Design Process
Creating Conditions for a C3N
1. Align motivation around common vision
2. Make it easy to contribute
– design, system engineering and technology
3. Enable better communication
4. Reduce “transactional” costs
Percent of Patients in Remission
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Jul-2007 N
=338
Aug-2
007 N
=396
Sep-2
007 N
=428
Oct-
20
07 N
=4
79
Nov-2
007 N
=508
Dec-2
007 N
=531
Jan-2
008 N
=570
Fe
b-2
008 N
=607
Mar-
2008 N
=643
Ap
r-2
00
8 N
=6
54
May-2
008 N
=667
Jun-2
008 N
=671
Jul-2008 N
=686
Aug-2
008 N
=731
Sep-2
008 N
=754
Oct-
20
08 N
=8
01
Nov-2
008 N
=832
Dec-2
008 N
=901
Jan-2
009 N
=973
Fe
b-2
009 N
=995
Mar-
2009 N
=1021
Apr-
2009 N
=1070
May-2
009 N
=1112
Jun-2
009 N
=1194
Jul-2009 N
=1240
Aug-2
009 N
=1277
Sep-2
009 N
=1314
Oct-
2009 N
=1344
Nov-2
009 N
=1366
Dec-2
009 N
=1400
Jan-2
010 N
=1421
Fe
b-2
010 N
=1410
Mar-
2010 N
=1440
Apr-
2010 N
=1455
May-2
010 N
=1461
Jun-2
010 N
=1471
Jul-2010 N
=1489
Aug-2
010 N
=1518
Sep-2
010 N
=1547
Oct-
2010 N
=1576
Nov-2
010 N
=1985
Dec-2
010 N
=2032
Jan-2
011 N
=2043
Fe
b-2
011 N
=2065
Mar-
2011 N
=2124
Apr-
2011 N
=2191
May-2
011 N
=2206
Jun-2
011 N
=2272
Jul-2011 N
=2301
Aug-2
011 N
=2335
Pe
rce
nt
of
Pat
ien
ts
Month
Percent of IBD Patients in Remission (PGA)
Why Crohn’s as a Prototype?
• Number of patients small
• Few incentives for industry to invest in research
• No center has enough patients
• Teenagers especially likely to use Internet
communications
Reducing Transactional Costs Example: Data Collection
“Enhanced” Registry
• Research using distributed registry of 10,000 patients
• Automated Pre-visit Prompts
• Automated Physician Pre-Visit Planning
Infliximab and Thiopurine Treatment by Site
0%
10%
20%
30%
40%
50%
60%
70%
Sites
Perc
en
tag
e o
f C
D P
ati
en
ts
Infliximab Thiopurine
“Enhanced” Registry - Research